News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
The partners also aim to expand their work to Latin America for the first time
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Subscribe To Our Newsletter & Stay Updated
